OKYO Pharma Limited has filed for Fast Track designation with the U.S. FDA for its drug urcosimod, aimed at treating neuropathic corneal pain, a painful eye condition currently lacking an FDA-approved ...
Morning Overview on MSN
FDA to fast-track reviews of 3 psychedelic drugs after Trump directive
The FDA will put three psychedelic drug programs on an ultra-fast approval track, compressing review timelines from roughly ...
Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...
By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results